Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir

A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus

Portal hypertension is a common pathology in chronic liver disease, particularly in liver cirrhosis. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China. The basic reason for portal hypertension in HBV is the largely deposition of hepatic extracellular matrixes which causes high pressure in liver vessels. One of the most common symptoms of cirrhotic portal hypertension is gastroesophageal varices.The effective inhibition of HBV can partially stop or reverse liver fibrosis in patients with chronic Hepatitis and liver cirrhosis due to HBV and the anti-fibrotic strategy focusing on the regulation of hepatic extracellular matrix may have a great benefit. Therefore, antivirals therapy is also a basic treatment for low-grade cirrhotic portal hypertension. Fuzheng Huayu has been found to enhance the degradation of collagens in fibrotic liver and have a good action against liver fibrosis in patients with chronic hepatitis B. However, there are no high quality clinical evidences which can demonstrate if the combination of anti-viral and anti-fibrotic therapy can relieve the pressure of liver vessels and decline incidence rate and bleeding rate of gastroesophageal varices.

Study Overview

• Status: Unknown
• Conditions: Portal Hypertension
• Intervention / Treatment: Drug: Entecavir; Drug: Entecavir + Fuzheng Huayu

Detailed Description

The primary objective of this study is to establish the safety and efficacy of the combination of Entecavir and Fuzheng Huayu for reverse rate of gastroesophageal varices in patients with low-grade cirrhotic portal hypertension due to hepatitis B virus.

• Study Type: Interventional
• Enrollment (Anticipated): 192
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: JING LV, MD; Phone Number: +86-21-20256521; Email: liver125@126.com

Study Locations

• China
  • Shanghai, China
    • Recruiting
    • Shanghai Zhongshan Hospital
    • Contact: Wei Jiang
  • Shanghai, China
    • Recruiting
    • Ruijin Hospital
    • Contact: hui Wang
  • Shanghai, China
    • Recruiting
    • Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
    • Contact: Jing Lv; Phone Number: 021-20256409

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• More than 6 months history of serum positive HBsAg
• Abdominal ultrasonogram or CT scan or liver-biopsy specimen indicates liver cirrhosis
• Age 18-65
• Child-Pugh<7 (Stage A)
• Without portal hypertension（Endoscopy indicates no signs of gastroesophageal varices.）
• Low-grade of portal hypertension（Endoscopy indicates signs of gastroesophageal varices that is line shape without red wales or spots and less than 0.3cm of diameter.）
• The patient or the patient's guardian agrees to participate the random controlled trial and sign the Informed Consent Form.

Exclusion Criteria:

• Primary Lamivudine, Adefovir dipivoxil and Entecavir resistance
• Decompensated cirrhosis、The Child-Pugh score≥7
• Moderate grade of portal hypertension（Endoscopy indicates signs of gastroesophageal varices that is line shape with red wales or spots and less than 0.3cm of diameter,or snake large shape without red wales or spots and less than 1.0cm of diameter.）
• Severe grade of portal hypertension（Endoscopy indicates signs of gastroesophageal varices that is catenulate/nodular shape with or without red wales or spots and more than 1.0cm of diameter.）
• Decompensated liver cirrhosis Liver cancer
• Liver histology conform to other chronic liver disease cause (exclude fatty liver)
• Non-HBV avihepadnavirus infected acute and chronic hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, inherited metabolic liver disease, drug or toxic hepatitis, Alcoholic liver disease.
• Have psychiatric history or uncontrollable epilepsy patient.
• Uncontrollable diabetic patient
• History of Hemoglobin disease (such as Alpha globin generation barrier anemia, Sickle cell deficiency, Spherocytosis) or Hemolytic anemia patients caused by other reasons like autoimmunity.
• Severe background disease like chronic respiratory failure, circulatory failure, kidney failure etc.
• In situ organ transplantation (such as liver, kidney, lung and heart) or bone marrow transplantation and stem cell transplantation.
• Immunocompromised patients: such as HIV infection or take immunosuppressor or glucocorticoid (such as cyclosporin, azathioprine, adrenocortical hormone) within 3 months or chemotherapy drugs (such as cyclophosphamide, ammonia and cancer chemotherapy) and radioactive therapy.
• Gestation or lactation period women and women who plan to get pregnant during the study period.
• Patient who are allergy to the experimental drug.
• Using history of anti-viral or anti-fibrosis drug within 6 months.
• Patients who are participating other trials.
• Other situation where PI thinks the patient should be excluded.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Entecavir; Tablet with Entrcavir	Drug: Entecavir; The subjects will be taking 1 Entecavir tablet per day for 96 weeks.
Experimental: Entecavir + Fuzheng Huayu; Tablet Tablet with Entrcavir+ Tablet with Fuzheng Huayu	Drug: Entecavir + Fuzheng Huayu; The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of clinical events: Variceal hemorrhage, Ascites, Encephalopathy, etc	96 weeks
Grading varices	96 weeks
Noninvasive portal hypertension index	96 weeks
Incidence of Liver cancer	96 weeks

Collaborators and Investigators

• Sponsor: ShuGuang Hospital
• Collaborators: Shanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Public Health Clinical Center; Longhua Hospital
• Investigators: Principal Investigator: CHENGHAI LIU, PHD,MD, ShuGuang Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 5, 2018
• Primary Completion (Anticipated): June 1, 2020
• Study Completion (Anticipated): June 1, 2021

Study Registration Dates

• First Submitted: October 23, 2016
• First Submitted That Met QC Criteria: October 24, 2016
• First Posted (Estimate): October 26, 2016

Study Record Updates

• Last Update Posted (Actual): February 13, 2020
• Last Update Submitted That Met QC Criteria: February 11, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Keywords: Hepatitis B; Portal Hypertension; Fuzheng Huayu
• Additional Relevant MeSH Terms: Digestive System Diseases; Cardiovascular Diseases; Vascular Diseases; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Hypertension; Hepatitis B; Hepatitis; Hypertension, Portal; Anti-Infective Agents; Antiviral Agents; Entecavir
• Other Study ID Numbers: SGHLC20161023003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No